SCHEMBL4034610

SCHEMBL4034610

[CH2]N1CCN(C(=O)CCN)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
KMT2A Q03164 3/20 0.48
ALDH1A1 P00352 2/20 0.48
MEN1 O00255 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
KDM4E B2RXH2 1/20 0.48
USP2 O75604 1/20 0.48
CYP3A4 P08684 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
SIGMAR1 Q99720 2/20 0.46
ATM Q13315 1/20 0.43
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GNAI3 P08754 1/20 0.39
GNAI1 P63096 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 1/20 0.39
CACNA1G O43497 1/20 0.37
HRH2 P25021 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11032090 0.91 LMNA (0.56) LMNAKMT2AALDH1A1MEN1TDP1
SCHEMBL437880 0.91
SCHEMBL2682148 0.81 ATM (0.65) LMNAKMT2AALDH1A1MEN1TDP1
SCHEMBL4034615 0.80 KMT2A (0.51) LMNAKMT2AALDH1A1MEN1TDP1
SCHEMBL3920258 0.80 TDP1 (0.48) LMNAKMT2AALDH1A1MEN1TDP1
SCHEMBL2832300 0.79 ATM (0.62) KMT2AALDH1A1MEN1TDP1HPGD
SCHEMBL15224112 0.79 ATM (0.62) KMT2AALDH1A1MEN1TDP1HPGD
Hydrochloric Acid SCHEMBL856723 0.79 ATM (0.62) LMNAKMT2AALDH1A1MEN1TDP1
SCHEMBL6694116 0.79 ATM (0.62) KMT2AALDH1A1MEN1TDP1HPGD
Hydrochloric Acid SCHEMBL55554 0.78 KMT2A (0.50) LMNAKMT2AALDH1A1MEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048269-A1 CHEMICAL COMPOUNDS-821 ASTRAZENECA AB (SE) 2009-02-19 US disclosed
WO-2009022171-A1 PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS ASTRAZENECA AB (SE) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048269-A1 CHEMICAL COMPOUNDS-821 TGFBR1, TGFBR2, SMAD3 LMNA 2739/4885KMT2A 2976/4885ALDH1A1 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.